重组人生长激素治疗肝硬变低蛋白血症腹水的临床研究

Clinical trial of recombinant human growth hormone in liver cirrhosis patients with hypoproteinemia and ascites

目的 探讨重组人生长激素对肝硬变低蛋白血症、腹水的疗效。方法 选择肝硬变腹水病人33例 ,随机分为重组人生长激素 (rhGH)治疗组 16例 ,对照组 17例。治疗组每晚睡前皮下注射rhGH 4U ,10d为 1个疗程 ;对照组每周补白蛋白 2 0g ,10d为 1个疗程。分别在治疗前、后检测两组的血浆白蛋白、空腹血糖、血脂并监测肾功能 ;观察 2 4h尿量及腹水的消退情况。结果 治疗后治疗组血浆白蛋白明显增加 ,腹水消退明显 ,与对照组相比差异有显著意义 (P均 <0 0 5 )。结论 重组人生长激素有明显促进肝硬变病人血清白蛋白合成的作用 ,具有临床应用价值。

Objective To study the clinic effect of recombinant human growth hormone on liver cirrhosis patients with hypoproteinemia and ascites.Methods Thirty three patients with liver cirrhosis and ascite were randomly divided into 2 groups.Sixteen patients were treated with recombinant human growth hormone(4U,daily) subcutaneously per night for 10 days.Seventeen patients received conventional medical treatment by the administration of 20 grams albumin per week for ten days.Plasma levels of albumin,fasting plasma glucose and total plasma cholesterol concentrations were detected before and after treatment.Renal functional state was monitered as well.Total day urine volume and the extinction of ascites were recorded.Results Plasma concentrations of albumin in the recombinant human growth hormone group increased greatly and lose more ascites than those in control group after treatment.The changes were more significant in the patients than those in controls(P<0.05).Conclusion Recombinant human growth hormone possesses active properties on albumin anabolic metabolism and hold great promise in the treatment of patients with cirrhosis.